Skip to main content
SpringerLink
Log in

Pharmacokinetic Drug Interactions with Anti-Ulcer Drugs

  • Review Article
  • Drug Interactions
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

The safety profile of any pharmacological agent is defined on the basis of its toxicity, tolerability and potential for pharmacokinetic and/or pharmacodynamic interactions with other compounds, which may belong to the same or to a different pharmacological class.

Drug-drug interactions are important in clinical practice because short and long term therapeutic regimens frequently require coadministration of different drugs.

The pharmacological treatment of gastric and duodenal ulcers (and of related syndromes) includes older and newer compounds, which have different mechanisms of action and exert different therapeutic effects. These compounds are widely prescribed in combination with other drugs being given for the treatment of concomitant diseases.

This article reviews pharmacokinetic interactions with anti-ulcer drugs, paying particular attention to those which have clinically relevant adverse effects. Drugs mentioned in the literature as causing any pharmacokinetic interaction with anti-ulcer compounds are considered in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Campbell WB, Halushka PV. Autacoids from lipids: eicosanoids and PAF. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the parmacological basis of therapeutics. 9th ed. New York: Pergamon Press Inc., 1996.

    Google Scholar 

  2. Itthipanichpong C, Sirivongs P, Wittayalertpunya S, et al. The effect of antacids on aspirin pharmacokinetics in healthy Thai volunteers. Drug Metabol Drug Interact 1992; 10: 213–28.

    PubMed  CAS  Google Scholar 

  3. Gontarz N, Small RE, Comstock TJ, et al. The effect of antacid suspension on the pharmacokinetics of ibuprofen. Clin Pharm 1987; 6: 413–6.

    PubMed  CAS  Google Scholar 

  4. Kivisto KT, Neuvolen PJ. Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide. Eur J Clin Pharmacol 1992; 42: 675–9.

    PubMed  CAS  Google Scholar 

  5. Kivisto Kt, Neuvonen PJ. Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide. Eur J Clin Pharmacol 1991; 40: 383–6.

    PubMed  CAS  Google Scholar 

  6. Desmond PV, Harman PJ, Gannouilis N, et al. The effect of an antacid and food on the absorption of cimetidine and ranitidine. J Pharm Pharmacol 1990; 42: 352–4.

    PubMed  CAS  Google Scholar 

  7. Tuynman HARE, Festen HPM, Rohs K, et al. Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules. Br J Clin Pharmacol 1987; 24: 833–5.

    PubMed  CAS  Google Scholar 

  8. Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs: an update. Clin Pharmacokinet 1990; 18: 210–9.

    PubMed  CAS  Google Scholar 

  9. Janknegt R. Drug interactions with quinolones. J Antimicrob Chemother 1990; 26 Suppl. D: 7–29.

    Google Scholar 

  10. Granneman GR, Stephan U, Birner B, et al. Effect of antacid medication on the pharmacokinetics of temafloxacin. Clin Pharmacokinet 1992; 22 Suppl. 1: 83–9.

    Google Scholar 

  11. Petitjean O, Brion N, Tod M, et al. Pharmacokinetics interaction of cefixime and 2 antacids: preliminary results. Presse Med 1989; 18: 1596–8.

    PubMed  CAS  Google Scholar 

  12. Verbeeck RK. Pharmacokinetic drug interactions with nonsteroideal anti-inflammatory drugs. Clin Pharmacokinet 1990; 19: 44–66.

    PubMed  CAS  Google Scholar 

  13. Caille G, DuSouich P, Vezina M, et al. Pharmacokinetic interaction between flurbiprofen and antacids in healthy volunteers. Biopharm Drug Dispos 1989; 10: 607–15.

    PubMed  CAS  Google Scholar 

  14. Gaspari F, Vigano G, Locatelli M, et al. Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodyalisis. Am J Kidney Dis 1988; 11: 338–42.

    PubMed  CAS  Google Scholar 

  15. Desager JP, Harvengt C. Oral bioavailability of nizatidine and ranitidine concurrently administered with antacids. J Int Med Res 1989; 17: 62–7.

    PubMed  CAS  Google Scholar 

  16. Nguyen VX, Nix DE, Gillikin S, et al. Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. Antimicrob Agents Chemother 1989; 33: 434–6.

    PubMed  CAS  Google Scholar 

  17. Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminium hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1992 36: 830–2.

    PubMed  CAS  Google Scholar 

  18. Rubinstein E, Segev S. Drug interactions of ciprofloxacin with other non-antibiotic agents. Am J Med 1987; 82: 119–23.

    PubMed  CAS  Google Scholar 

  19. Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antiacid and an H2 receptor antagonist. Antimicrob Agents Chemother 1992; 36: 796–800.

    PubMed  CAS  Google Scholar 

  20. De Bernardi di Valserra M, Feletti F, Berte F, et al. Lack of effect of a single dose of sulglicotide on the bioavailability of diclofenac. Eur J Clin Pharmacol 1988; 34: 211–2.

    PubMed  Google Scholar 

  21. Ungethum W. Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. Drug Res 1991; 41: 797–800.

    CAS  Google Scholar 

  22. Caille G, DuSouich O, Gervais P, et al. Effects of concurrent sucralfate administration on pharmacokinetics of naproxen. Am JMed 1987; 83: 67–73.

    CAS  Google Scholar 

  23. Pai S, Melethiol S, Cuddy P, et al. Elevation of serum aluminium in humans on a two-day sucralfate regimen. J Clin Pharmacol 1987; 27: 213–5.

    PubMed  CAS  Google Scholar 

  24. Miller LG, Prichard JG, White CA, et al. Effect of concurrent sucralfate administration on the absorption of erythromycin. J Clin Pharmacol 1990; 30: 39–44.

    PubMed  CAS  Google Scholar 

  25. Marks IN. Sucralfate-safety and side effects. Scand J Gastroenterol 1991; 26: 36–42.

    Google Scholar 

  26. Parpia SH, Nix DE, Hejmanowski LG, et al. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 1989; 33: 99–102.

    PubMed  CAS  Google Scholar 

  27. Rey AM, Gums JG. Altered absorption of digoxin, sustained release quinidine, and warfarin with sucralfate administration. DICP 1991; 26: 745–6.

    Google Scholar 

  28. Deppermann KM, Lode H, Hoffken G, et al. Influence of ranitidine, pirenzepine, and aluminium magnesium hydroxide on the bioavailability of various antibiotics, including amoxicilllin, cephalexin, doxycycline, and doxycycline-clavulanic acid. Antimicrob Agents Chemother 1989; 33: 1901–7.

    PubMed  CAS  Google Scholar 

  29. Seibert Grafe M, Pidgen A. Lack of effect of multiple dose sucralfate on the pharmacokinetics of roxatidine acetate. Eur J Pharmacol 1991; 40: 637–8.

    CAS  Google Scholar 

  30. Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketaconazole bioavailability. Antimicrob Agents Chemother 1991; 35: 1765–71.

    PubMed  CAS  Google Scholar 

  31. Dixon JS, Page MC. Interactions between non-steroidal anti-inflammatory drugs and H2-receptor antagonists or prostaglandin analogues. Rheumatollnt 1991; 11: 13–8.

    CAS  Google Scholar 

  32. Small RE, Cox SR, Adams WJ. Influence of H2 receptor antagonists on the disposition of flurbiprofen enantiomers. J Clin Pharmacol 1990; 30: 660–4.

    PubMed  CAS  Google Scholar 

  33. Delhotal-Landes B, Flouvat B, Liote F, et al. Pharmacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2-receptor antagonists (cimetidine or ranitidine) in human volunteers. Clin Pharmacol Ther 1988; 44: 442–52.

    PubMed  CAS  Google Scholar 

  34. Dixon JS, Lacely LF, Pickup ME, et al. Alack of pharmacokinetic interaction between ranitidine and piroxicam. Eur J Clin Pharmacol 1990; 39: 583–6.

    PubMed  CAS  Google Scholar 

  35. Said SA, Foda AM. Influence of cimetidine on the pharmacokinetic of piroxicam in rat and in man. Drug Res 1989; 39: 790–2.

    CAS  Google Scholar 

  36. Evans AM, Nation Rl, Samson LN. Lack of effect of cimetidine on the pharmacokinetic of R()- and S (+)-ibuprofen. Br J Clin Pharmacol 1989; 28: 143–9.

    PubMed  CAS  Google Scholar 

  37. Verbeeck RK, Corman CL, Wallace SM, et al. Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. Eur J Clin Pharmacol 1988; 35: 521–7.

    PubMed  CAS  Google Scholar 

  38. Collins JD, Pidgen AW. Pharmacokinetics of roxatidine in healthy volunteers. Drugs 1988; 35 Suppl. 3: 41–7.

    Google Scholar 

  39. Skoutakis VA. Comparison of the parenteral histamine-2-receptor antagonists. Ann Pharmacother 1989; 23 Suppl. 10: 17–22.

    Google Scholar 

  40. Forsyth DR, Jayasinghe KSA, Roberts CJC. Do nizatidine and cimetidine interact with ibuprofen? Eur J Clin Pharmacol 1988; 35: 85–8.

    PubMed  CAS  Google Scholar 

  41. Sorgel F, Granneman GR, Stephan U, et al. Effect of cimetidine on the pharmacokinetic of temafloxacin. Clin Pharmacokinet 1992; 22 Suppl. 1: 75–82.

    PubMed  Google Scholar 

  42. Davis RL, Quenzer RW, Kelly HW, et al. Effect of the addition of ciprofloxacin on theophylline pharmacokinetics in subjects inhibited by cimetidine. Ann Pharmacother 1992; 26: 11–3.

    PubMed  CAS  Google Scholar 

  43. Puff MR, Carey WD. The effect of cimetidine on cyclosporine A levels in liver transplant recipients: a preliminary report. Am J Gastroenterol 1992; 87: 287–91.

    PubMed  CAS  Google Scholar 

  44. Knupp CA, Graziiano FM, Dixon RM, et al. Pharmacokinetic interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob Agents Chemother 1992; 36: 2075–9.

    PubMed  CAS  Google Scholar 

  45. Kosoglou T, Perentesis GP, Affrime MB, et al. The effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304. J Clin Pharmacol 1990; 30: 638–42.

    PubMed  CAS  Google Scholar 

  46. Eradiri O, Jamali F, Thompson AB. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn’s disease. Biopharm Drug Dispos 1988; 9: 219–27.

    PubMed  CAS  Google Scholar 

  47. Flynn RJ, Moore J, Collier PS, et al. Single-dose oral H2-anatgonists do not affect plasma lidocaine levels in the parturient. Acta Anaesthesiol Scand 1989; 33: 593–6.

    PubMed  CAS  Google Scholar 

  48. Pihlajamaki KK, Lindberg RLP, Jantunen ME. Lack of effect of cimetidine on the pharmacokinetics of bupivacaine in healthy subjects. Br J Clin Pharmacol 1988; 26: 403–6.

    PubMed  CAS  Google Scholar 

  49. Kuhnert BR, Zuspan KJ, Kuhnert PM, et al. Lack of influence of cimetidine an bupivacaine levels during parturition. Anaesth Analg 1987; 66: 986–90.

    CAS  Google Scholar 

  50. Brockmeyer NH, Breithaupt H, Ferdinand W, et al. Kinetics of oral and intravenous mexiletine: lack of effects of cimetidine and ranitidine. Eur J Clin Pharmacol 1989; 36: 375–8.

    PubMed  CAS  Google Scholar 

  51. Stringer KA, Lebsack ME, Cetnarowski-Cropp AB, et al. Effect of cimetidine administration on the pharmacokinetics of pirmenol. J Clin Pharmacol 1992; 32: 91–4.

    PubMed  CAS  Google Scholar 

  52. Rodvold KA, Palouceck FP, Jung D, et al. Interaction of steadystate procainamide with H2-receptor antagonist cimetidine and ranitidine. Ther Drug Monit 1987; 9: 378–83.

    PubMed  CAS  Google Scholar 

  53. Bauer LA, Black D, Gensler A. Procainamide-cimetidine drug interaction in elderly male patients. J Am Geriatr Soc 1990; 38: 467–9.

    PubMed  CAS  Google Scholar 

  54. Asgharnejad M, Powell JR, Donn KH, et al. The effect of cimetidine dose timing on oral propanolol kinetics in adults. J Clin Pharmacol 1988; 28: 339–43.

    PubMed  CAS  Google Scholar 

  55. Rey E, Jammet P, d’Athis P, et al. Effect of cimetidine on the pharmacokinetics of the new beta-blocker betaxolol. Arzeneimittel Forscung 1987; 37: 953–6.

    CAS  Google Scholar 

  56. Schwartz JB, Upton RA, Lin ET, et al. Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmaccol Ther 1988; 43: 673–80.

    CAS  Google Scholar 

  57. Toon S, Davidson EM, Garstang FM, et al. The racemic metoprolol H2-antagonist interaction. Clin Pharmacol Ther 1988; 43: 283–9.

    PubMed  CAS  Google Scholar 

  58. Somogyi AA, Bochner F, Sallustio BC. Stereos elective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther 1992; 51: 379–87.

    PubMed  CAS  Google Scholar 

  59. Huang SM, Weintraub HS, Marriott TB, et al. Etintidine-propranolol interaction study in humans. J Pharmacokinet Biopharm 1987; 15: 557–68.

    PubMed  CAS  Google Scholar 

  60. Krishna DR, Klotz U. Newer H2-receptor antagonists: clinical pharmacokinetics and drug interaction potential. Clin Pharmacokinet 1988; 15: 205–15.

    PubMed  CAS  Google Scholar 

  61. Labs RA. Interaction of roxatidine acetate with antacids, food and other drugs. Drugs 35: Suppl. 3: 82–9.

  62. Khan A, Langley SJ, Mullins FG, et al. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol 1991; 32: 519–22.

    PubMed  CAS  Google Scholar 

  63. Muck W, Wingender W, Seiberling M, et al. Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in health volunteers. Eur J Clin Pharmacol 1992; 42: 325–8.

    PubMed  CAS  Google Scholar 

  64. Kirch W, Halabi A, Linde M, et al. Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements. Gastroenterology 1989; 96: 1388–92.

    PubMed  CAS  Google Scholar 

  65. Rodger RSC, Muralikrishna GS, Halls DJ, et al. Ranitidine suppresses aluminium absorption in man. Clin Sci 1991; 80: 505–8.

    PubMed  CAS  Google Scholar 

  66. Soons PA, Vogels BA, Roosemalen MC, et al. Grapefruitjuice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991; 50: 394–403.

    PubMed  CAS  Google Scholar 

  67. Mikus G, Eichelbaum M, Fisher C, et al. Interaction of verapamil and cimetidine: stereochemical aspeccts of drug metabolism, drug dispostion and drug action. J Pharmacol Exp Ther 1990; 253: 1042–8.

    PubMed  CAS  Google Scholar 

  68. Mouser B, Nykamp D, Murphy JE, et al. Effect of cimetidine on oral digoxin absorption. DICP 1990; 24: 286–8.

    PubMed  CAS  Google Scholar 

  69. Kochack GM, Rakhit A, Thompson TN, et al. Pentopril-cimetidine interaction caused by a reduction in hepatic blood flow. J Clin Pharmacol 1988; 28: 222–7.

    Google Scholar 

  70. Ferry JJ, Cetnarowsky AB, Sedman AJ, et al. Multiple dose cimetidine administartion does not influence the single-dose pharmacokinetics of quinapril and its active metabolite. J Clin Pharmacol 1988; 28: 48–51.

    PubMed  CAS  Google Scholar 

  71. Muirhead M, Bochner F, Somogyi A. Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption. J Pharmacol Exp Ther 1988; 244: 734–9.

    PubMed  CAS  Google Scholar 

  72. Klotz U, Gottlieb W, Keohane PP, et al. Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. J Clin Pharmacol 1987; 27: 210–2.

    PubMed  CAS  Google Scholar 

  73. Suttle AB, Songer SS, Dukes GE, et al. Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. J Clin Psychopharmacol 1992; 12: 282–7.

    PubMed  CAS  Google Scholar 

  74. Vanderveen RP, Jirca JL, Peters GR, et al. Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin Pharm 1991; 10: 539–43.

    PubMed  CAS  Google Scholar 

  75. Huloven R, Desager JP, Cox S, et al. Influence of repeated administration of cimetidine on the pharmacokinetics and pharmacodynamics of adinazolam in healthy subjects. Eur J Clin Pharmacol 1988; 35: 59–64.

    Google Scholar 

  76. Dal Negro R, Pomari C, Zoccatelli O, et al. Pharmacokinetics of theophylline and H2 antagonist drugs, cimetidine and ranitidine. Int J Clin Pharmacol Ther Toxicol 1984; 22: 221–6.

    Google Scholar 

  77. Dal Negro R, Turco P, Pomari C, et al. Combined administration of controlled release theophylline and ranitidine: a 53-day controlled survey in patients with chronic obstructive lung disease (COLD) and peptic ulcer. Br J Clin Pract 1987; 41: 1004–8.

    Google Scholar 

  78. Dal Negro R, Turco P, Zoccatelli O, et al. H2-antagonist derangement of the kinetics of sustained-release oral theophylline. Int J Clin Pharmacol Ther Toxicol 1985; 23: 329–32.

    Google Scholar 

  79. Adebayo GT, Mabadeie AF. Theophylline disposition effects of cimetidine, mebendazole and albendazole. Pharmacol Ther 1988; 2: 341–6.

    CAS  Google Scholar 

  80. Mauro VF, Mauro LS, Hageman JH. Alteration of pentoxifylline pharmacokinetics by cimetidine. J Clin Pharmacol 1988; 28: 649–54.

    PubMed  CAS  Google Scholar 

  81. Gaska JA, Tietze KJ, Rocci Jr ML, et al. Theophylline pharmacokinetics: effect of continuous versus intermittent cimetidine i.V. infusion. J Clin Pharmacol 1991; 31: 668–72.

    PubMed  CAS  Google Scholar 

  82. Shaheen O, Sliman NA, Turk WA. Effect of cimetidine on the pharmacokinetics of theophylline. Gen Pharmacol 1988; 19: 431–4.

    PubMed  CAS  Google Scholar 

  83. Huang SM, Weintraub HS, Marriott TB, et al. Etintidine-theophylline interaction study in humans. Biopharm Drug Dispos 1987; 8: 561–9.

    PubMed  CAS  Google Scholar 

  84. Kelly HW. Lack of evidence for reduction of theophylline clearance by ranitidine [letter]. Am J Med 1989; 86: 629–32.

    PubMed  CAS  Google Scholar 

  85. Lin JH, Chremos AN, Chiou R, et al. Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. Br J Clin Pharmacol 1987; 24: 669–72.

    PubMed  CAS  Google Scholar 

  86. Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 1991; 21: 178–94.

    PubMed  CAS  Google Scholar 

  87. Verdiani P, di Carlo S, Baronti A. Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD. Chest 1988; 94: 807–10.

    PubMed  CAS  Google Scholar 

  88. Dal Negro R, Pomari C, Turco P. Famotidine and theophylline pharmacokinetics. An unaspected cimetidine-like interaction in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet 1993; 24: 255–8.

    Google Scholar 

  89. Kendall MJ, Gibson R, Walt RP. Co-administration of misoprostol or ranitidine with indomethacin: effects on pharmacikinetics, abdominal symptoms and bowel habit. Aliment Pharmacol Ther 1992; 6: 437–46.

    PubMed  CAS  Google Scholar 

  90. Rainsford PA, James C, Hunt RH, et al. Effects of misoprostolon the pharmacokinetics of indomethacin in human volunteers. Clin Pharmacol Ther 1992; 51: 415–21.

    PubMed  CAS  Google Scholar 

  91. Hsyu PH, Cox JW, Pullen RH, et al. Pharmacokinetic interactions between erbaprostil and aspirin in humans. Biopharm Drug Dispos 1989; 10: 411–22.

    PubMed  CAS  Google Scholar 

  92. Bennett PN, Fenn GC, Notarianni LJ, et al. Misoprostol does not alter the pharmacokinetics of propranolol. Postgrad Med J 1991; 67: 455–7.

    PubMed  CAS  Google Scholar 

  93. de Lauture D, Rey E, d’Athis P, et al. Pharmacokinetic interactions between theophylline and rioprostil. Scand J Gastroenterol 1989; 164 Suppl.: 63–6.

    Google Scholar 

  94. Thyssen HH, Hamulyak K. The interaction of the prostaglandin E derivate rioprostil with oral anticoagulant agents. Clin Pharmacol Ther 1989; 46: 110–6.

    Google Scholar 

  95. Garris RE, Kirkwood CF. Misoprostol: a prostaglandin E1 analogue. Clin Pharm 1989; 8: 627–44.

    PubMed  CAS  Google Scholar 

  96. Winters L, Wilberg C. Enprostil, a synthetic prostaglandin E2 analogue, does not affect oral contraceptive bioavailability. Curr Ther Res 1988; 44: 46–50.

    CAS  Google Scholar 

  97. Kirch W, Janisch HD, Santos SR. Influence of cisapride and metoclopramide on digoxin bioavailability. Eur J Clin Pharmacol 1986; 11: 249–50.

    CAS  Google Scholar 

  98. Van der Klejin E, Van Marmeren C. Effects of cisapride on the clinical response of propranolol on blood pressure in mildy hypertensive patients. Janssen International Report, 1987.

  99. Bateman DN. The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur J Clin Pharmacol 1986; 30: 205–8.

    PubMed  CAS  Google Scholar 

  100. Mauran Ph, Crine L, Zerrouck N, et al. Etude de l’interaction pharmacocinetique entre la theophylline et le cisapride. Proceedings of the 5th Congres Francaise de Pharmacie Clinique; 1991 Dec 5–6; Paris.

    Google Scholar 

  101. Rowbotam DJ, Milligan K, McHugh P. Effect of single doses of cisapride and ranitidine administered simultaneously on plasma concentrations of cisapride and ranitidine. Br J Anaesth 1991; 67: 302–5.

    Google Scholar 

  102. Kirch W, Janisch HD, Ohnhaus EE, et al. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit 1989; 11: 411–4.

    PubMed  CAS  Google Scholar 

  103. Barzaghi N, Crema F, Mescoli G, et al. Effects on cimetidine bioavailability of metoclopramide and antacids given two hours apart. Eur J Clin Pharmacol 1989; 37: 409–10.

    PubMed  CAS  Google Scholar 

  104. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21: 195–212.

    PubMed  CAS  Google Scholar 

  105. Humphries TJ. Clinical implications of drug interactions with the cytochrome P450 enzyme system associated with omeprazole. Dig Dis Sci 1991; 36: 1665–9.

    PubMed  CAS  Google Scholar 

  106. Oosterhuis B, Jonkman JH. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion 1989; 44 Suppl. 1: 9–17.

    Google Scholar 

  107. Hansten PD. Drug interactions with antisecretory agents. Aliment Pharmacol Ther 1991; 5 Suppl. 1: 121–8.

    Google Scholar 

  108. Blohme I, Idstrom JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol 1993; 35: 156–60.

    PubMed  CAS  Google Scholar 

  109. Henry D, Brent P, Whyte I, et al. Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 1987; 33: 369–73.

    PubMed  CAS  Google Scholar 

  110. Cavanaugh JH, Schenech DW, Mukherji D, et al. Lack of effect of concomitant lansoprazole on single-dose propanolol pharmacokinetics and pharmacodynamics. Gastroenterology 1994; 106 (4): A4.

    Google Scholar 

  111. Andersson T, Lundborg P, Regardh CG. Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. Eur J Clin Pharmacol 1991; 40: 61–5.

    PubMed  CAS  Google Scholar 

  112. Koch HJ, Hartmann M, Bliesath H, et al. Pantoprazole does not influence metoprolol pharmacokinetics and pharmacodynamics in man. Gastroenterology. In press.

  113. Ching MS, Elliott SL, Stead CK, et al. Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. Aliment Pharmacol Ther 1991; 5: 523–31.

    PubMed  CAS  Google Scholar 

  114. Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 1991; 32: 569–72.

    PubMed  CAS  Google Scholar 

  115. Soons PA, van den Berg G, Danhof M, et al. Influence of singleand multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 1992; 42: 319–24.

    PubMed  CAS  Google Scholar 

  116. Bliesath H, Huber R, Hartmann M, et al. Pantoprazole does not influence the steady state pharmacokinetics of nifedipine. Gastroenterology 1994; 106 (4): 55.

    Google Scholar 

  117. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Pharmacol 1987; 24: 543–5.

    CAS  Google Scholar 

  118. Middle MV, Muller FO, Schall R, et al. No influence of pantoprazole on pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 1995; 33: 304–7.

    PubMed  CAS  Google Scholar 

  119. Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmaccol 1992; 34: 509–12.

    CAS  Google Scholar 

  120. Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 1995; 39: 700–3.

    PubMed  CAS  Google Scholar 

  121. Cavanaugh JH, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on steady state warfarin metabolism [abstract]. Gastroenterology 1991; 100: A40.

    Google Scholar 

  122. Andersson T, Andren K, Cederberg C, et al. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 1990; 39: 51–4.

    PubMed  CAS  Google Scholar 

  123. Gugler R, Hartmann M, Rudi J, et al. Lack of interaction of pantoprazole and diazepam in man [abstract]. Gastroenterology 1992; 102: A77.

    Google Scholar 

  124. Lefebvre RA, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992; 52: 458–63.

    PubMed  CAS  Google Scholar 

  125. Oosterhuis B, Jonkman JH, Andersson T, et al. No influence of single intravenous doses of omeprazole on theophylline elimination kinetics. J Clin Pharmacol 1992; 32: 470–5.

    PubMed  CAS  Google Scholar 

  126. Taburet AM, Geneve J, Bocquentin M, et al. Theophylline steady state pharmacokinetics is not altered by omeprazole. Eur J Clin Pharmacol 1992; 42: 343–5.

    PubMed  CAS  Google Scholar 

  127. Schulz HU, Hartmann M, Steinijans VW, et al. Lack of influence of pantoprazoleon the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 1991; 29: 369–75.

    PubMed  CAS  Google Scholar 

  128. Granneman G, Winters EP, Locke CS, et al. Lack of effect of concomitant lansoprazole on steady state theophylline pharmacokinetics [abstract]. Gastroenterology 1990; 100: A75.

    Google Scholar 

  129. Kokufu T, Ihara N, Sugioka N, et al. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 1995; 48: 391–5.

    PubMed  CAS  Google Scholar 

  130. Granneman G, Locke CS, Cavanaugh JH. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 1995; 17 (5): 460–4.

    PubMed  CAS  Google Scholar 

  131. Fuchs W, Sennewald R, Klotz U. Lansoprazoole does not affect the bioavailability of oral contraceptives. Br J Clin Pharmacol 1994; 38: 376–80.

    PubMed  CAS  Google Scholar 

  132. Middle MV, Muller FO, Schall R, et al. Effect of pantoprazole on ovulation suppression by a low-dose hormonal contraceptive. Clin Drug Invest 1995; 9: 54–6.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Lung Clinical Pathophysiology, Bussolengo General Hospital, Azienda Sanitaria, ULSS N22, Verona, Italy

    Roberto Dal Negro

Authors
  1. Roberto Dal Negro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Negro, R.D. Pharmacokinetic Drug Interactions with Anti-Ulcer Drugs. Clin Pharmacokinet 35, 135–150 (1998). https://doi.org/10.2165/00003088-199835020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199835020-00003

Keywords

Search

Navigation